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Increasing evidence has linked dysregulated interleukin
(IL)-10 production by IL-10ve B cells to autoimmunity, high-
lighting the importance of improving the understanding of the
regulation of IL-10 production in these cells. In both B cells and
myeloid cells, IL-10 can be produced in response to Toll-like
receptor (TLR) agonists. In macrophages, previous studies have
established that mitogen- and stress-activated protein kinases
(MSKs) regulate IL-10 production via the phosphorylation of
cAMP response element–binding (CREB) protein on the
IL-10 promoter. We found here that although MSKs are acti-
vated in peritoneal B cells in response to TLR4 agonists, neither
MSKsnorCREBare required for IL-10 production in these cells.
Using a combination of chemical inhibitors and knockout mice,
we found that IL-10 induction in B cells was regulated by an
ERK1/2- and p90 ribosomal S6 kinase-dependent mechanism,
unlike in macrophages in which p90 ribosomal S6 kinase was
not required. This observation highlights fundamental differ-
ences in the signaling controlling IL-10 production in B cells
andmacrophages, even though these two cell types respond to a
common TLR stimulus.
IL-102 is an important anti-inflammatory cytokine that plays
important roles in limiting inflammation, as evidenced by the
development of inflammatory bowel disorders, in both mice
and humans, following the loss of IL-10 function (1–3). IL-10
can be produced by a number of cell types, including myeloid
cells, T cells, and B cells, in response to a range of different
stimuli (reviewed in Refs. 4–6). In vivo IL-10 hasmultiple roles;
however, a major component of its anti-inflammatory function
is to repress the production of pro-inflammatory cytokines by
macrophages and dendritic cells (4–6). Despite its strong anti-
inflammatory properties, recombinant IL-10 has not proven to
be successful for the treatment of autoimmune disorders (7).
This suggests that the timing and location of IL-10 production
and/or action are critical for its protective effects. Support for
this idea has come from the use of conditional IL-10 knockout
mice. Loss of IL-10 specifically in the T-cell compartment was
sufficient to promote the development of colitis, whereas mye-
loid-specific IL-10 deletion did not result in the development of
colitis but did sensitize mice to LPS-mediated endotoxic shock
(8, 9). Furthermore, transfer of IL-10–competent immune cells
can be protective in autoimmunemodels in mice. For example,
transfer of B cells with the potential to make IL-10 has been
found to be protective in mouse models of arthritis, autoim-
mune encephalomyelitis lupus, and colitis (10–15). Although
initially described in mice, IL-10–producing B cells have now
been identified and have been found to be decreased in several
autoimmune conditions including lupus, rheumatoid arthritis,
psoriasis, and multiple sclerosis (reviewed in Ref. 16).
The molecular mechanisms behind the regulation of IL-10
production have been studied mainly in T cells and macro-
phages and differences exist between these cell types in terms of
the stimuli and transcription factors that regulate IL-10 tran-
scription (reviewed in Refs. 4–6). In both myeloid and B cells,
the activation of pattern recognition receptors, notably mem-
bers of the Toll-like receptor (TLR) family, have been found to
be effective stimuli for inducing IL-10 production (17–19).
Much of our understanding about how TLRs drive IL-10 pro-
duction has come from studies on macrophages and dendritic
cells. In these cells, stimulation of TLRs results in the transcrip-
tional activation of the IL-10 gene, thereby giving rise to
increased IL-10 protein production and secretion. TLRs acti-
vate the MAPK and NFB pathways, and inhibition of these
pathways can prevent TLR-induced cytokine production (20,
21). In the context of IL-10, the ERK1/2 and p38 MAPK path-
ways have been shown to be important for the control of IL-10
production inmacrophages (22). Both ERK1/2 and p38 are able
to activate downstream kinases; p38 activates the related
kinases MK2 and MK3, whereas ERK1/2 is able to activate
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RSK1, 2, and 3 (23). p38 and ERK1/2 are both able to activate
MSK1 and 2 and for stimuli, such as TLR agonists, that activate
both ERK1/2 and p38; inhibition of both pathways is required
to prevent MSK activation (24). Although the role of RSK in
IL-10 induction has not been addressed, roles for bothMSK1/2
and MK2/3 have been identified in macrophages. MK2 has
been reported to reduce IL-10 production by LPS–stimulated
bone marrow–derived macrophages (BMDMs) (25). MK2 is
known to phosphorylate proteins such as TTP that regulate the
stability of cytokine mRNAs (26). Consistent with this, MK2
knockout decreased IL-10 mRNA stability (25). Double knock-
out of MSK1 and 2 impairs IL-10 production in both BMDMs
and dendritic cells (27–29). In this context MSKs activate the
transcription factor CREB by phosphorylating it on Ser133,
resulting in the induction of CREB–dependent genes (30). Sim-
ilar to MSK1/2 knockouts, BMDMs from mice with a Ser133 to
Ala knockin mutation in CREB show decreased IL-10 tran-
scription in response to LPS (27). The importance of CREB for
the induction of IL-10 in macrophages has been further illus-
trated by the identification of CREB–binding sites in the IL-10
promoter (22, 31, 32). Furthermore, PGE2 can synergistically
activate IL-10 transcription in combination with LPS, a process
that requires the nuclear translocation of a CREB co-activator
protein, CRTC3 (33, 34).
In mice, B cells can be divided into B1 and B2 lineages (35).
Most B2 cell subsets do not appear to make appreciable
amounts of IL-10 following stimulation. Instead the production
of IL-10 is limited to specific subsets that have been termed B10
or regulatory B cells (reviewed in Refs. 36–39). Adoptive trans-
fer of these cells has been shown to be protective in multiple
immune models in mice. In addition to specific B2 cell subsets,
some B1 cells also have the ability to make IL-10. At present, a
master transcription factor has not been identified for the
development of IL-10–producing B cells, nor has a unique cell
surface maker been found to allow their easy identification. It
is possible that IL-10–producing B cells do not represent a
unique lineage, with several B-cell subsets having the ability to
secrete IL-10 under specific circumstances (36–39).
In mice, the peritoneal cavity is a rich source of IL-10 com-
petent B cells. Unlike splenic B cells, in which only 1–2% of B
cell make IL-10, between 20 and 40% of peritoneal cavity B cells
are able to produce IL-10 in response to TLR stimulation (39,
40). Little is known about the intracellular pathways controlling
IL-10 production in B cells. Here, we show that B cells and
macrophages regulate IL-10 production by distinct mecha-
nisms in response to TLR stimulation.
Results
Peritoneal cavity B cells andmacrophages produce IL-10 in
response to ex vivo TLR stimulation
In unchallenged mice, the peritoneal cavity contains a num-
ber of immune cells types with a high proportion of these cells
being macrophages or B cells, both of which have the potential
to produce cytokines in response to TLR agonists. To deter-
mine whether both peritoneal macrophages and B cells pro-
duce IL-10, peritoneal cells were sorted into pure (98%) pop-
ulations of B cells (CD19ve cells) and macrophages (F4/
80ve cells) by FACS. The cells were then LPS–stimulated and
secretion of IL-10 measured. Both purified macrophages and B
cells secreted IL-10 in response to LPS (Fig. 1A). IL-10 induc-
tion after ex vivo LPS stimulation of unsorted peritoneal cells
was also assessed using a flow cytometry assay as described
under “Materials and methods.” The cells were simultaneously
stained for lineagemarkers for B cells (CD19) andmacrophages
(F4/80) and intracellular IL-10. In this assay, both B cells
(CD19ve) and macrophages (F4/80ve) produced IL-10 fol-
lowing LPS stimulation (Fig. 1,B andC). The ability of B cells to
induce IL-10 was not restricted to TLR4 agonists, because CpG
(TLR9 agonist), Pam3CSK4 (TLR1/2 agonist), and CL097
(TLR7/8 agonist) were also able to induce IL-10 in peritoneal B
cells (Fig. 1, B and C). Intracellular staining for IL-10 showed
that some IL-10 induction could be seen as early as 2 h after LPS
stimulation, with levels increasing with time and starting to
plateau at 5 h after LPS stimulation (Fig. 1D). Peritoneal B cells
are a mix of different subsets. Simultaneous analysis of cell sur-
face markers and IL-10 production in LPS–stimulated B cells
showed that most of the IL-10–producing B cells were CD19hi
and expressed high levels of CD1d, CD5, and IgMbut low levels
of IgD (Fig. S1), consistent with the cells belonging to the B1a
subset.
In macrophages, LPS–dependent cytokine production can
be inhibited by knockout of the Myd88 signaling adaptor. In
line with this, Myd88 knockout reduced IL-10 production in
peritoneal B cells (Fig. 2A). To confirm that the role of Myd88
was cell intrinsic in the B cells, LPS stimulations were carried
out ex vivo on a mixed culture of peritoneal cells from
CD45.2ve Myd88 knockout mice and CD45.1ve wildtype
mice. This confirmed that loss of Myd88 specifically in the B
cells could block LPS–induced IL-10 production (Fig. 2B).
MAPK signaling is activated downstream of TLR activation in B
cells and is required for IL-10 production
LPS activates a number of signaling cascades, of which the
ERK1/2 and p38 play a central role in IL-10 induction inmacro-
phages (20).We therefore looked at the ability of LPS to activate
these pathways in the peritoneal B cell andmacrophage subsets.
LPS–stimulated cells were stained intracellularly using fluoro-
phore-labeled phospho-ERK1/2 (p-ERK1/2) and phospho-p38
(p-p38) antibodies that recognize these kinases when they are
phosphorylated on their TXY activation motifs. Strong phos-
phorylation of ERK1/2 (Fig. 3A) and p38 (Fig. 3B) was seen in
macrophages by 20 min of LPS stimulation, which then
decreased over time. In B cells, the response was slower with
little or no ERK1/2 phosphorylation seen at 20 min; however,
p-ERK1/2 was seen at 60 min, which was sustained and still
apparent at 180 min (Fig. 3A). Like ERK1/2, p38 phosphoryla-
tion in B cells was both delayed and weaker compared with that
observed in macrophages (Fig. 3B). To confirm these results,
peritoneal cells were sorted into purified populations of B
cells and macrophages by FACS prior to LPS stimulation, and
immunoblotting was used to assess ERK1/2 and p38 phosphor-
ylation. Corroborating the flow cytometry data, ERK1/2 and
p38 phosphorylation was seen in LPS–stimulated purified B
cells; however, phosphorylation of these kinases was weaker
and delayed compared with that seen inmacrophages (Fig. 3C).
RSK1 and 2 regulate IL-10 induction in B cells
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Treatment of peritoneal cells before LPS stimulationwith the
MKK1/2 inhibitor PD184352, which blocks the activation of
ERK1/2, reduced the secretion of IL-10 (Fig. 3D). The p38/
inhibitor VX-745 resulted in a similar reduction in IL-10 pro-
duction. ERK1/2 and p38 are known to have some common
substrates in cells including MSK1 and 2 (20), and a combina-
tion of PD184352 andVX-745 resulted in stronger inhibition of
IL-10 production than either inhibitor on its own (Fig. 3D).
Measurement of cytokine levels present in the media from
mixed cell cultures does not distinguish between cytokine
secretion by the B-cells andmacrophage subsets. To determine
whether the ERK1/2 and p38pathways regulate IL-10 produc-
tion in B cells andmacrophages, the experiments were repeated
using intracellular IL-10 staining as the readout. Treatment of
peritoneal cells with PD184352 or VX-745 prior to LPS stimu-
lation reduced IL-10 induction in B cells, whereas a combina-
tion of both PD184352 and VX-745 blocked IL-10 production
(Fig. 3E). PD184352 andVX-745 also reduced IL-10 production
in peritoneal macrophages (Fig. 3E), consistent with what has
been published in bonemarrow–derivedmacrophages (22, 27).
TLR–induced IL-10 production in B cells is independent of
MSK1/2 and CREB activation
In bone marrow–derived macrophages, LPS–induced IL-10
production has previously been shown to be dependent on the
kinasesMSK1 and 2, which act downstreamof both the ERK1/2
and p38 MAPK pathways. In these cells, MSKs act via phos-
phorylating the transcription factor CREB to promote the tran-
scription of CREB dependent genes (27, 28).
To examine MSK activation in B cells, B cells and macro-
phages were purified from the peritoneal cavity cells via mag-
netic sorting, as described under “Materials and methods.”
MSK1 activation requires it to be phosphorylated on Thr581 by
theupstreamMAPK(41).LPSstimulation inducedThr581phos-
phorylation of MSK1 in both peritoneal B cells and macro-
phages fromwildtypemice (Fig. 4A). LPS also induced thephos-
phorylation of CREB and the related transcription factor ATF1
in wildtype, but not MSK1/2 knockout, B cells (Fig. 4A). As
expected, CREB phosphorylation following LPS stimulation in
isolatedmacrophageswas alsoMSK–dependent (Fig. 4A). Sim-
ilar results were also obtained from B cells isolated by FACS
(data not shown). These data show that LPS stimulation acti-
vated theMSK1/2–CREB pathway in peritoneal B cells, similar
to what was observed in peritoneal macrophages (Fig. 4A).
Next, the role of MSK and CREB in LPS–stimulated IL-10
induction in peritoneal cells was examined. Intracellular IL-10
staining in peritoneal cells from MSK1/2 knockout or CREB
S133Aknockinmice (inwhich theMSKphosphorylation site in
CREB, Ser133, has beenmutated to alanine) was compared with
staining in peritoneal cells from matched wildtype control
mice. Consistent with previous studies in BMDMs (27, 28),
MSK1 andMSK2 double knockout (Fig. 4B) or S133Amutation
of CREB (Fig. 4C) reduced IL-10 induction by peritoneal
macrophages. Unexpectedly, and in contrast to the results in
macrophages, in the same experiments neitherMSK1/2 knock-
out nor theCREBS133Aknockin had any effect on the ability of
peritoneal B cells to produce IL-10 in response to LPS (Fig. 4, B
andC). Recently IL-10 induction in B cells has been reported to
be reduced byNaphtholAS-E (42), a compound that can inhibit
the interaction of CREB with its co-activator protein CBP (43,
44). The interaction of CREB and CBP required CREB to be
phosphorylated on Ser133, and it has previously been shown
that CBP is not recruited to CREB in cells from the S133A
knockin mice. We therefore tested the effect of Naphthol AS-E
on IL-10 induction. Inwildtype peritoneal cells, Naphthol AS-E
reduced IL-10 induction in B cells in response to LPS and
blocked IL-10 induction in macrophages (Fig. 5, A and B). To
test whether this inhibition was due to an on target effect of the
inhibitor, peritoneal cells were isolated frommicewith a S133A
knockin mutation in CREB (which blocks CBP recruitment)
and a knockout of theCREB–related transcription factorATF1.
Naphthol AS-E reduced IL-10 induction in the B cells from
these mice to a similar extent as seen in wildtype cells (Fig. 5C),
suggesting that the effect of this compound was not acting via
CREB. In line with this, Naphthol AS-E also reduced IL-10
induction in MSK1/2 knockout cells (Fig. 5D). Together, these
data show that, unlike macrophages, B-cell IL-10 production is
not regulated by MSK1/2 or CREB phosphorylation.
RSK andMK2/3 are required formaximal TLR-induced IL-10
production in B cells
The above data show that ERK1/2 and p38 MAPK signaling
regulate TLR–induced IL-10 production in B cells, but that
unlike inmacrophages this does not requireMSK1 and 2 down-
stream of MAPK activation. We therefore assessed the poten-
tial role of other ERK1/2 and p38 MAPK–activated kinases in
B-cell IL-10 production.
The p38-activated kinases MK2 and MK3 have previously
been implicated in regulating the induction of several cyto-
kines, including IL-10, in macrophages (25). In agreement with
this MK2/3 double knockout BMDMs secreted significantly
less IL-10 than wildtype BMDMs, in response to LPS stimula-
tion (Fig. 6A). Similarly, on LPS stimulation peritoneal cavity
macrophages from MK2/3 double knockout mice showed
reduced IL-10 induction compared with macrophages from
wildtype mice (Fig. 6B). Peritoneal cavity B cells also showed
reduced IL-10 induction, but the decrease was less pronounced
than that in macrophages (Fig. 6B). In agreement with this,
Figure 1. TLR stimulation induced IL-10 production by peritoneal cavity B cells and macrophages. A, cells were isolated from the peritoneal cavity of
wildtype mice and FACS sorted into pure populations of B cells and macrophages as described under “Materials and methods.” The cells were either left
unstimulated (control) orwere stimulatedwith 10g/ml LPS for 16 h. Culture supernatantwas harvested, and concentration of secreted IL-10was determined
by a Luminex assay. The data shown aremeans standard deviation of biological quadruplicates (n 4). B, peritoneal cavity cells were stimulated ex vivowith
10 g/ml LPS, 1 g/ml Pam3CSK, 5 g/ml CL-097, or 4 g/ml CpG in the presence of Golgi inhibitors, 3 g/ml brefeldin A, and 2 M monensin for 5 h. Cells
treatedwith 3g/ml brefeldin A and 2Mmonensin but without LPS stimulationwere used as controls (con). Subsequently, the cells were stained for lineage
markers, CD19 (B cells) and F4/80 (macrophages), and for intracellular IL-10, as described underMaterials andmethods.” The graphs represent themeans and
standard deviation for the percentage of IL-10ve cells in the B-cell andmacrophage gates as assessed by flow cytometry (n 3).C, representative FACS plots
from B are shown.D, peritoneal cells fromwildtypemicewere treatedwith 3g/ml brefeldin A, 2Mmonensin, and 10g/ml LPS for the indicated times. The
level of intracellular IL-10 in the B-cell macrophage populations was determined by flow cytometry.
RSK1 and 2 regulate IL-10 induction in B cells
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inhibition of MK2/3 in wildtype cells with theMK2/3 inhibitor
PF3644022 also had an inhibitory effect on IL-10 induction in B
cells (Fig. 6C).
Next, we explored the role of kinases downstream of ERK1/2
signaling in regulating B-cell IL-10 production. The RSK family
of kinases comprises four members in mammalian cells (RSK1,
Figure 2. Effect ofMyd88 knockout on IL-10 induction by LPS.A, peritoneal cavity cells fromwildtype orMyd88 knockout (KO) micewere either stimulated
with 10g/ml LPS brefeldin Amonensin for 5 h. Intracellular IL-10 in B cells andmacrophages were assessed by flow cytometry. Representative plots are
shown in the left panels. The data shown in the right panels are the average percentages of IL-10 cells standard deviation of biological replicates (n 3 for
wildtype, n 5 for Myd88 knockout). ***, p 0.001 (Student’s two-tailed unpaired t test). B, peritoneal cavity cells from CD45.1ve wildtype and CD45.2ve
Myd88 knockoutmice were isolated, and equal numbers of cells from each genotypeweremixed. The cells were then stimulated ex vivowith 10g/ml LPS
brefeldinAmonensin for 5 h. The cellswere stained for CD45.1, CD45.2, CD19, and IL-10 and analyzedby flowcytometry. Representative plots for IL-10 in the
B-cell population (CD19ve) and non–B-cell population (CD19ve) are shown, and the graphs represent the means standard deviation of four biological
replicates. *, p 0.05; **, p 0.01 (Student’s two-tailed unpaired t test).
RSK1 and 2 regulate IL-10 induction in B cells
2306 J. Biol. Chem. (2018) 293(7) 2302–2317
 at U
N
IV
ERSITY
 O
F D
U
N
D
EE on February 26, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
RSK1 and 2 regulate IL-10 induction in B cells
J. Biol. Chem. (2018) 293(7) 2302–2317 2307
 at U
N
IV
ERSITY
 O
F D
U
N
D
EE on February 26, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
2, 3, and 4) and is related to MSK1 and 2. RSK1, 2, and 3 are
activated in cells by ERK1/2, whereas RSK4 has been suggested
to be constitutively active (reviewed in Refs. 23 and 45). RSK
was activated in B cells by LPS, as judged by phosphorylation on
Thr359/Ser363, sites which are phosphorylated by ERK1/2 and
correlate with RSK activation (46). To test the requirement of
RSK signaling for B-cell IL-10 production, experiments were
carried out using both RSK inhibitors and RSK knockout mice.
LJI308 has recently been reported to be a specific RSK inhibitor
(47, 48). To determine theworking concentration of LJI308 and
to assess its specificity, LJI308 was titrated on PMA–stimulated
HeLa cells (Fig. S2A). In these cells, PMA activates ERK1/2,
which in turn activates RSK to promote GSK3 phosphorylation
and MSK1/2 to promote CREB phosphorylation (30, 49).
GSK3/ can also be phosphorylated by Akt (49); therefore,
these experiments were done in the presence of the PI3K inhib-
itor GDC0941 to block the PI3K–Akt pathway. A concentra-
tion of 10 M of LJI308 could block GSK3/ phosphorylation
without affecting CREB phosphorylation, confirming that
LJI308 was selective for RSK over MSK in cells (Fig. S2A). Fur-
thermore in vitro screening of LJI308 against a panel of 140
kinases at 0.1M showed that only RSK1 and RSK2 were inhib-
Figure 3. ERK1/2 and p38 regulate LPS–induced IL-10 production. A and B, peritoneal cavity cells fromwildtype mice were stimulated with 10 g/ml LPS
for the indicated times andwere stained for p-ERK1/2 (A), p-p38 (B), and CD19 and F4/80 lineagemarkers. Representative plots are shown for the p-ERK1/2 and
p-p38 signals in the CD19 B-cell and F4/80macrophagepopulation (black line) overlaid on the basal signal in unstimulated controls (gray, filled). The results are
representativeof three independent experiments.C, peritoneal cavity cells fromwildtypemicewere FACS sorted intopureB-cell andmacrophagepopulations
as described under “Materials andmethods” before stimulationwith 10g/ml LPS for the indicated times. Phospho- and total levels of ERK1/2 andp-p38were
assessed by immunoblotting. D, peritoneal cavity cells from wildtype mice were cultured at 2  106 cells/ml. The cells were either incubated with 2 M
PD284352 (PD), 1 M VX-745 (VX) as indicated or with 0.1% DMSO for 1 h prior to stimulation with 10 g/ml LPS for 16 h. Culture supernatant was harvested,
and concentration of secreted IL-10was determined by a Luminex assay. The data shown aremeans standard deviation of biological quadruplicates (n 4).
One-way ANOVA for the effect of inhibitor treatment on the IL-10 concentration was significant (F(4,15) 1514, p 0.001). For pairwise comparisons with
LPS–stimulated cells without inhibitor using the Holm–Sidak method, *** indicates p  0.001. E, peritoneal cavity cells from wildtype mice were either
incubatedwith 2M PD284352, 1M VX-745 as indicated or with 0.1%DMSO for 1 h prior to stimulationwith 10g/ml LPS brefeldin Amonensin for 5 h.
Intracellular IL-10 in B cells andmacrophageswas assessedby flowcytometry. Representative plots are shown in the left panel, and thegraphs in the right-hand
panel represent the averages and standard deviation of biological replicates (n 4). One-way ANOVA for the effect of inhibitor treatment on the percentage
of IL-10–positive cells was significant in B cells (F(3,12)  72.037, p  0.001) and macrophages (F(3,12)  38.8, p  0.001). For pairwise comparisons with
LPS–stimulated cells without inhibitor using the Holm–Sidak method, *** indicates p 0.001. Con, control.
Figure4.MSKandCREBregulateLPS–induced IL-10production inmacrophagesbutnotBcells.A, B-cell andmacrophagepopulationswere isolated from
peritoneal cavity cells fromwildtype andMSK1/2 double knockoutmice. The cells were treated for the indicated timeswith 10g/ml LPS or left unstimulated.
The levels of the indicated proteins were assessed in cell lysates by immunoblotting. Long and short exposures of the phosphor-CREB/ATF1 blot are shown to
allow visualization of both phospho-CREB (upper band) and phospho-ATF1 (lower band). B and C, peritoneal cavity cells from wildtype, MSK1/2 double
knockout (B), and CREB S133A knockin (C) mice were stimulated with 10 g/ml LPS  brefeldin A  monensin for 5 h. Intracellular IL-10 in B cells and
macrophageswas assessed by flow cytometry. Representative plots are shown in the left panels. The data shown in the right panels represent the averages and
standard deviations of biological replicates (n 12 in B, n 6 in C). ***, p 0.001 (two-tailed unpaired Student’s t test).
RSK1 and 2 regulate IL-10 induction in B cells
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ited by more than 80%. RSK3 and RSK4 were not in the panel,
and LJI308 did not show inhibition of MSK1, MK2, or MK3 in
this assay (Fig. S2D). Assessment of IL-10 induction by intra-
cellular staining in LPS–stimulated wildtype peritoneal cavity
cells showed that LJI308 inhibited IL-10 induction in the B-cell
subset but not in macrophages (Fig. 7A). Similar experiments
were done with two other inhibitors: SB747651A, which has
previously been shown to inhibit RSK in addition toMSKs (50);
and Cmp-20, which has been reported as a dual RSK/MSK
inhibitor (51). Titration of these inhibitors on PMA stimulated
HeLa cells showed that either 10 M Cmp-20 (Fig. S2B) or 10
M SB747651A (Fig. S2C) was sufficient to inhibit both RSK
and MSK, as assessed by immunoblotting for GSK3/ and
CREB phosphorylation, respectively. Both SB747651A and
Cmp-20 inhibited LPS–induced IL-10 production in peritoneal
B cells form wildtype mice (Fig. S3A). Because these com-
pounds target both MSK and RSK, this experiment was
repeated in cells fromMSK1/2 knockout mice where any effect
of the inhibitor would be independent of MSKs. Again, both
SB747651A and Cmp-20 inhibited IL-10 production in perito-
neal B cells from MSK1/2 knockout mice (Fig. S3B). Taken
together, these data are consistent with a role for RSK in regu-
lating B-cell IL-10 production.
Four isoforms of RSK have been described, of which RSK1,
RSK2, and RSK3 are activated by the ERK1/2 pathway (23, 45).
Interrogation of the ImmGen database indicated that the
mRNA levels for RSK1 andRSK2were higher than the levels for
RSK3 and RSK4 in peritoneal B cells (Fig. S3C). To examine the
role that RSK1 and RSK2 might play in IL-10 regulation in B
cells, peritoneal cells were isolated from RSK1, RSK2, and
RSK1/2 knockout mice. Double knockout of both RSK1 and
RSK2 reduced LPS–stimulated IL-10 production relative to
wildtype cells (Fig. 7, B and C). Single knockout of either RSK1
or RSK2 resulted in an intermediate effect, suggesting that
there is compensation between RSK1 and RSK2 (Fig. 7, B and
C). RSK1/2 knockout did not affect LPS–induced IL-10 produc-
tion in peritoneal macrophages (Fig. 7, B and C). IL-10 produc-
tion can potentially be regulated at multiple stages. To deter-
mine whether IL-10 could be regulated by RSK at the level of
mRNA induction, RNA was isolated from peritoneal B cell
stimulated in the presence or absence of the RSK inhibitor
LJI308. This showed that RSK inhibition decreased the induc-
tion of IL-10 mRNA in response to LPS (Fig. 7D). mRNA levels
can be affected by both changes in transcription and mRNA
stability. Because the levels of the primary unspliced transcript
of a gene can give a better indication of changes in transcription
than mRNA levels, this was also analyzed for IL-10. As for the
mRNA, the induction of the primary transcript for IL-10 in
response to LPS was reduced by LJI308 (Fig. 7D). Overall, data
from RSK inhibitor and RSK knockout mice experiments sup-
port a central role for RSK signaling in the regulation IL-10
production in B cells.
Discussion
The ability of certain B-cell subsets to make IL-10 has
emerged as an important control mechanism in the immune
system (reviewed in Refs. 36 and 37). The majority of these
studies have focused on the development and function of
IL-10–producing B cells, rather than on the intracellular sig-
naling that controls IL-10 production, which has remained
largely uncharacterized. Knockout of the Ca2 sensors STIM1
and STIM2 inhibits B-cell IL-10 production, suggesting a role
for Ca2 in the development or function of IL-10–producing B
cells (52). Downstream of Ca2, a role for NFAT has been pro-
posed based on the use of calcineurin inhibitors (52, 53),
although another study found the effect of calcineurin inhibi-
tors on IL-10 was independent of NFAT (54). CD40 ligation in
human tonsillar B cells has been found to induce IL-10 mRNA,
and this was blocked by a p38 inhibitor (55). p38/ and
MEK1/2 inhibitors have also been found to reduce LPS–
induced IL-10 secretion inmurine splenic cultures enriched for
B cells (56). In line with this, we find that LPS–induced IL-10
production in peritoneal B cells was reduced by inhibitors of the
ERK1/2 and p38 MAPK pathways and that combining inhibi-
tors of both pathways had an additive effect.
The molecular mechanism of TLR–induced IL-10 produc-
tion has been more extensively studied in macrophages. In
these cells, ERK1/2 and p38 MAPK pathways converge on the
activation of MSK1 and 2. MSKs phosphorylate CREB, thereby
activating its ability to drive IL-10 transcription (22, 27, 57–62).
The studies reported here support the role for MSK and CREB
inTLR–induced IL-10 production inmacrophages. In contrast,
they show that in peritoneal B cells, TLRs regulate IL-10 inde-
pendently of MSKs and CREB, even though MSK catalyzed
CREB phosphorylation occurs in B cells. A role for CREB reg-
ulating IL-10 in peritoneal B cells has recently been suggested
based on the use of CREB–CBP interaction inhibitor Naphthol
AS-E (42). Similar to Aziz et al. (42), we also found that Naph-
thol AS-E reduced IL-10 induction in wildtype B cells. This
compound is not a direct CREB inhibitor; instead it binds to the
KIX domain in CBP and prevents the interaction of the CBP
KIXdomainwith the phosphorylatedKIDdomain of CREB (43,
44). As a result, it prevents CBP recruitment to CREB and
reduces the activation of CREB-dependent genes. Phosphoryl-
ation of Ser133 in the KID domain of CREB is also required for
CBP recruitment (30), and therefore the use of Naphthol AS-E
in the S133A knockin cells can distinguish between CREB–de-
pendent and –independent effects of the compound. Because
Naphthol AS-E reduced IL-10 induction in CREB S133A
knockin B cells, the effects of Naphthol AS-E in this case are
likely to be CREB–independent. The mechanism of action of
Naphthol AS-E in B-cell IL-10 regulation is unclear. CBP can
act as a co-activator for a large number of transcription factors,
and for some of these, such as c-Myb, p53, and FOXO3a, CBP is
Figure 5. Naphthol AS-E inhibits IL-10 induction in B cells independently of CREB phosphorylation. A and B, wildtype peritoneal cells were incubated
with 20 M Naphthol AS-E for 1 h. The cells were then either stimulated with 10 g/ml LPS brefeldin Amonensin for 5 h or treated with brefeldin A
monensin alone.A andB, intracellular IL-10 in B cells (A) andmacrophages (B) was assessedby flowcytometry. Representative plots are shown in the left panels.
The data shown in the right panels represent the averages  standard deviations of three stimulations. ***, p  0.001 relative to the LPS–stimulated cells
(two-tailed unpaired Student’s t test). C, as in A except peritoneal cells were isolated from CREB S133A/ATF1 KO mice. D, as in A except peritoneal cells were
isolated fromMSK1/2 double knockout mice.
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recruited via interactions with its KIX domain (reviewed in
Refs. 63 and 64). It is not known whether the binding of Naph-
thol AS-E to the CBP KIX domain blocks the recruitment of
CBP to these transcriptions factors. It is, however, possible that
the effect of Naphthol AS-E on IL-10 is due to it blocking CBP
binding to a transcription factor distinct from CREB. Alterna-
tively, it may be that Naphthol AS-E exerts effects in cells inde-
pendent of CBP.
Our studies indicate that the control of IL-10 in B cells
is independent of CREB and MSKs. Instead the ERK1/2–
activated kinases RSK1 andRSK2 regulated IL-10 production in
peritoneal B cells but not macrophages. A role for ERK1/2 in
IL-10 induction has been observed in macrophages stimulated
with Schistosoma mansoni excretory products, which was sug-
gested to be RSK–dependent (65). Although this study did find
evidence of RSK phosphorylation in macrophages, it did not
directly look at the effect of RSK inhibition on IL-10 induction
or CREB phosphorylation, and the data presented in the study
on p38 and ERK1/2 inhibition on IL-10 fits with the canonical
MSK–CREB dependent pathway in macrophages. Of note, we
show here that neither RSK1/2 knockout nor a selective RSK
inhibitor blocked LPS–induced IL-10 production in macro-
phages. Taken together, the results indicate that macrophages
and B cells use distinct mechanisms to regulate IL-10 down-
stream of ERK1/2 and highlights that immune cell–specific dif-
ferences in signaling occur downstream of a common receptor.
Materials andmethods
Reagents
DMEM, PBS, RPMI, L-glutamine, and penicillin-streptomy-
cin were from Life Technologies (Invitrogen); EDTA was from
Ambion; 2-mercaptoethanol, DMSO, and BSA were from Sig-
ma; non-essential amino acids, sodium pyruvate, and HEPES
buffer were from Lonza; brefeldin A and monensin were from
eBiosciences; fetal calf serum (FCS) was from Labtech. LPS
from Escherichia coli 026:B6 was from Sigma. CL-097 (TLR7/8
agonist), Pam3CSK4 (TLR1/2 agonist), and CpG (ODN1826,
TLR9 agonist) were from InvivoGen.
Antibodies
Flow cytometry antibodies to CD19 (clone eBio1D3), IL-10
(clone JEs5-16E3), TNF (clone MP6-XT22), IgM (clone
11/41), and IgD (clone 11-26c.2a) were from eBiosciences;
F4/80 (clone BM8), CD1d (clone 1B1), and CD5 (clone 53-7.3)
were from BioLegend; IL-6 (clone MP5-20F3) was from BD
Biosciences; anti-rabbit IgG Fab2–PE conjugate was from Cell
Signaling Technology; and rat anti-mouse CD16/CD32 Fc
blockTM (clone 2.4G2) was from BD PharmingenTM. Western
blotting antibodies to total MSK1 and total RSK2 were made
in-house. Phospho-ERK1/2 (Thr202/Tyr204) (catalog no. 9101),
total ERK1/2 (catalog no. 9102), phospho-p38 (Thr180/Tyr182)
(catalog no. 4511), total p38 (catalog no. 9212), phospho-CREB
(Ser133)/phospho-ATF1 (Ser63) (catalog no. 9198), total CREB
(catalog no. 9197), phospho-MSK1 (Thr581) (catalog no. 9595),
phospho-GSK3/ (S21/S9) (catalog no. 9331), phospho-RSK
(Thr359/Ser363 numbered for human RSK1) (catalog no. 9344),
and total GAPDH (catalog no. 2118) were from Cell Signaling
Technology.
Inhibitors
The ERK1/2 inhibitor PD184352 was from Axon and was
used at a final concentration of 2M. The p38 inhibitor VX-745
was from Selleck and was used at a final concentration of 1 M.
The PI3K inhibitor GDC-0941 was from Axon and was used at
a final concentration of 1 M. TheMK2/3 inhibitor PF3644022
was from Tocris and was used at a final concentration of 5 M.
These concentrations were used because they have previously
been established to inhibit the target kinases in cultured cells
(50, 66, 67). The N-terminal MSK1/2 inhibitor SB747651A,
which also inhibits RSK, was from Axon and was used at a final
concentration of 10 M. The C-terminal RSK/MSK1/2 inhibi-
tor compound 20 (51) was generated in-house and was used at
a final concentration of 10 M. The RSK inhibitor LJI308 (47,
48) was also generated in-house and was used at a final concen-
tration of 10 M unless otherwise stated. The selectivity of
PD184352, VX745, and SB747641 has been published previ-
ously (33, 50, 66). The selectivity of LJI308 is given in Fig. S2.
The CREB–CBP interaction inhibitor Naphthol AS-E (CAS
92-78-4) was from Calbiochem and used at 20 M.
Mice
MSK1, MSK2, RSK1, RSK2, MK2, and MK3 knockout mice
have been described previously (33, 68–72). To generate the
CREB S133A mouse, animals with a conditional CREB S133A
knockin (71) were crossed onto a Vav-Cre transgenic back-
ground (73) to generate the knockin in hematopoietic cells.
Where indicated theCREBmicewere crossed to anATF1 S63A
knockin line, in which the mutated exon was flanked by loxP
sites. When crossed to the Vav-Cre transgene, this resulted in
immune cells with an S133A mutation in CREB and knockout
of AFT1. All mice were maintained on a C57Bl/6 background
(12 generations). The mice were housed in individually ven-
tilated cages at 21 °C, 55–65% humidity, and a 14/10-h light/
dark cycle. The mice were provided with free access to food
(R&M3) and water and kept under specific pathogen-free
conditions.
Figure6.MK2and3contribute toLPS–induced IL-10production.A, BMDMswere cultured fromwildtypeandMK2/3double knockout (DKO)mice. The cells
were stimulatedwith 100ng/ml LPS for the indicated times, and the levels of IL-10 in the culture supernatantwere determinedusing a Luminex assay. Thedata
show themeans standard deviation from cultures from fourmice/genotype. B, peritoneal cavity cells fromwildtype andMK2/3 double knockoutmicewere
stimulatedwith 10g/ml LPSbrefeldin Amonensin for 5 h. Intracellular IL-10 in B cells andmacrophageswas assessed by flow cytometry. Representative
plots are shown in the left panels. The data shown in the right panels represent the averages standard deviations of biological replicates (n 4). C, peritoneal
cavity cells from wildtype mice were incubated with 5 M PF3644022 for 1 h prior to stimulation with 10 g/ml LPS  brefeldin A  monensin for 5 h.
Intracellular IL-10 levels in B cellswas assessed by flow cytometry. Representative plots are shown in the left panels. The data shown in the right panel represent
the averages standard deviations of biological replicates (n 7). *, p 0.05; **, p 0.01; ***, p 0.001 compared with LPS–stimulatedWT cells (two-tailed
unpaired Student’s t test).
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Cell isolation and culture
Murine peritoneal cavity was flushed with peritoneal cavity
wash buffer (PBS 1% BSA 2mM EDTA) by carefully inject-
ing in 5–10 ml of buffer, gently massaging the abdomen, and
collecting/aspirating the buffer with a syringe. Isolated cells
were cultured in RPMI medium supplemented with 4 mM
L-glutamine, 100 units/ml penicillin, 100 g/ml streptomycin,
10mMHEPES buffer, 100M (1) non-essential amino acids, 1
mM sodium pyruvate, 50 M 2-mercaptoethanol, and 10% heat
inactivated FCS (peritoneal cell culture medium). Where indi-
cated, the cells were treated with inhibitors for 1 h before stim-
ulation. The cells were stimulated with 10 g/ml LPS in the
presence of Golgi inhibitors, 3 g/ml brefeldin A, and 2 M
monensin. The cells treated with 3 g/ml brefeldin A and 2 M
monensin but without LPS stimulation were used as controls.
The cells were incubated at 37 °C, 5% CO2 for 5 h, unless indi-
cated otherwise.
Bone marrow–derived macrophages were isolated as previ-
ously described (74) and cultured in BMDM (DMEM supple-
mented with 10% heat-inactivated fetal bovine serum, 2 mM
L-glutamine, 100 units/ml of penicillin G, 100 g/ml of strep-
tomycin, 0.25 g/ml of amphotericin [Invitrogen], and 5 ng/ml
of macrophage colony-stimulating factor; PreProTech). HeLa
cells were cultured in DMEM supplemented with 10% FBS, 2
mM L-glutamine, 100 units/ml of penicillin G, and 100g/ml of
streptomycin and serum-starved for 16 h before stimulation.
Flow cytometry
Cytokine staining—The cells were isolated, cultured, and
stimulated as above. Sequentially, the cells were washed with
FACS buffer (PBS 1% BSA), fixed using fixation buffer (eBio-
sciences) for 20 min at 4 °C, washed with FACS buffer, per-
meabilized with 1 permeabilization buffer (eBiosciences) for
15 min at 4 °C, washed with FACS buffer, incubated with
1:100 Fc block made up in 1 permeabilization buffer for 10
min at 4 °C, washed with FACS buffer, and incubated with
antibodies (1:100 CD19, 1:200 F4/80 and 1:100 IL-10 made up
in 1 permeabilization buffer for 30 min at 4 °C. (Note that
CD19 and F4/80 antibodies recognize fixed antigen; therefore
extracellular CD19 and F4/80 staining and intracellular cyto-
kine staining could be performed in a single step after fixing and
permeabilizing cells.) Stained cells were washed with FACS
buffer, resuspended in FACS buffer, and acquired on a BD
FACSCantoTM II.
Phosphoprotein staining—The cells were stimulated with
LPS in the absence of Golgi inhibitors for the indicated times.
The cells were fixed by adding ice-cold fixation buffer (two
times the volume of media) to cells in media and incubating for
20 min on ice. The cells were washed with cold FACS buffer
and permeabilized with ice-cold 90% methanol/distilled water,
added slowly while vortexing to prevent cell clumping, for 30
min on ice. The cells were washed twice with excess FACS
buffer to get rid of the methanol before incubation first with
1:100 Fc block in FACS buffer and then with phospho-protein
antibodies (1:50 p-ERK1/2 or 1:50 p-p38Western blotting anti-
bodies fromCell SignalingTechnologies) in FACS buffer for 1 h
at room temperature. The cells were washed twice with excess
FACS buffer and incubated with 1:1000 anti-Rabbit IgG Fab–PE
conjugate detection antibody  1:100 CD19  1:200 F4/80 in
FACSbuffer for 30min at room temperature in the dark. The cells
werewashed twicewithexcessFACSbuffer, resuspended inFACS
buffer, and acquiredon aBDFACSCantoTM II.All flowcytometry
data were analyzed using FlowJo software.
Fluorescence-activated cell sorting
The cells were isolated from the peritoneal cavity as above.
Isolated cells from identical genotypes were pooled and stained
for cell surface lineage markers, CD19 and F4/80, under sterile
conditions and using 0.22-m filter-sterilized reagents. Briefly,
the cells were pelleted and incubated sequentially with 1:100
filter-sterilized Fc block made up in FACS buffer for 10 min at
4 °C and with filter-sterilized antibodies (1:100 CD19 and
1:200 F4/80) made up in FACS buffer for 30 min at4 °C. The
cells were washed with sterile FACS buffer, resuspended in
sterile FACS buffer, and sorted into CD19 and F4/80 popu-
lations on a BD InfluxTM cell sorter into RPMI media contain-
ing 20% FCS. Sorted cells were pelleted and rested in peritoneal
cell culture media for 2 h at 37 °C, 5% CO2 before use in assays.
Western blotting
Peritoneal cavity cells were isolated as above. In some exper-
iments, the cells were sorted into B cells (CD19) and macro-
phages (F4/80) as described above, before stimulation. All
cells were rested for 2 h inmedia at 37 °C, 5%CO2 after isolation
with or without inhibitors for the last 1 h, before stimulation as
indicated in the figure legends. The cells were lysed in SDS lysis
buffer (Triton lysis buffer is 50 mM Tris-HCl, pH 7.5, 1 mM
EGTA, 1 mM EDTA, 1 mM sodium orthovanadate, 50 mM
sodium fluoride, 1 mM sodium pyrophosphate, 10 mM sodium
glycerophosphate, 0.27 M sucrose, 1% (v/v) Triton X-100. SDS
lysis buffer is Triton lysis buffer mixed with 10% (v/v) glycerol,
1% (w/v) SDS, and bromphenol blue) supplemented with 14.3
Figure 7. RSK regulated IL-10 production in LPS–stimulated B cells. A, peritoneal cavity cells fromwildtypemice were incubatedwith 10M LJI308 for 1 h
prior to stimulation with 10 g/ml LPS  brefeldin A  monensin for 5 h. Intracellular IL-10 in B cells and macrophages was assessed by flow cytometry.
Representative plots are shown in the left panels. The data shown in the right panel represent the averages standard deviations of biological replicates (n
4). ***, p value 0.001 comparedwith LPS–stimulated cells (two-tailed unpaired Student’s t test). B, peritoneal cavity cells fromwildtype, RSK1 knockout (KO),
RSK2 knockout, and RSK1/2 double knockout (DKO) micewere stimulatedwith 10g/ml LPSbrefeldin Amonensin for 5 h. Intracellular IL-10 in B cells and
macrophageswas assessedby flow cytometry. Representative plots are shown.C, quantification of data from B. The graphs represent the averages standard
deviations of biological replicates (n 13, 5, 8, and 4 for LPS–stimulatedWT, RSK1, RSK2, and RSK1/2, respectively). One-way ANOVA for LPS–treated samples
showed a that the effect of genotype on the percentage of IL-10–positive cells was significant in B cells (F(3,26) 10.745, p 0.001) but not macrophages
(F(3,26) 0.128, p 0.943). For pairwise comparisons with wildtype cells using the Holm–Sidak method, * indicates p 0.05, and ** indicates p 0.001. D, B
cells were purified formperitoneal washes fromwildtypemice as described under “Materials andmethods.” The cells were incubatedwith 10M LJI308 for 1 h
prior to stimulation with 10g/ml LPS for 2h. Total RNA was isolated, and induction of IL-10 mRNA and IL-10 primary (10) transcript was determined by qPCR
relative to unstimulated cells. Graphs show means standard deviations (n 5). **, p 0.01; ** p 0.001 compared with LPS–stimulated cells (two-tailed
Student’s t test). Con, control.
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mM 2-mercaptoethanol and protease inhibitors 1 g/ml apro-
tinin, 1 g/ml leupeptin, and 1 mM phenylmethylsulfonyl fluo-
ride. The sampleswere syringedwith a 25-gauge needle to shear
DNA and heated at 100 °C for 10 min to denature proteins
before running on a 10% SDS-polyacrylamide gel. Resolved
proteins were transferred to a nitrocellulose membrane, and
the membranes were probed for phospho- or total proteins as
indicated. Images were acquired on an Odyssey Fc Imaging
system (Li-Cor Biosciences) and analyzed using Image Studio
Lite software (Li-Cor Biosciences).
Analysis of secreted cytokines
Sorted cells (B cells ormacrophages)were cultured in 96-well
plates at 1  105 cells/well in 100 l of media. The cells were
stimulated with LPS in the absence of Golgi inhibitors, and
culture supernatant was harvested at the indicated incubation
times. Concentration of cytokines in the supernatant was
assessed using a Luminex-based multiplex assay (Bio-Plex
System; Bio-Rad) according to the manufacturer’s protocol.
qPCR
B cells were isolated from total peritoneal cavity cells by
positive selection using the magnetic antibody cell sorting sep-
aration system. The cells were stained with biotinylated anti-
mouse CD19 (BioLegend) followed by incubation with strepta-
vidinmicrobeads (Miltenyi Biotec), and B cells were purified on
a magnetic antibody cell sorting separation column (Miltenyi
Biotec). The purity of isolated B cells was routinely checked by
flow cytometry and determined to be 95%. Following isola-
tion cells were incubated in peritoneal cell culture media. For
qPCR, following stimulation, total RNA was isolated from 1
106 cells/sample using NucleoSpin RNA II purification kits
(Macherey–Nagel) and 250 ng of RNA reverse transcribed
using iScript (Bio-Rad). qPCR using SYBR Green–based
detection (Takara Biosciences) was carried out as previously
described (27, 75). Fold change was calculated relative to
unstimulated cells and corrected for levels of 18s as a loading
control. Primer sequences used were CCCTTTGCTATGGT-
GTCCTTTC and GATCTCCCTGGTTTCTCTTCCC for
IL-10 mRNA, CCAAGCCTTATCGGAAATGA and TTTGT-
TGGGTGGCTCTAAGG for the primary IL-10 transcript, and
GTAACCCGTTGAACCCCATT and CCATCCAATCGGT-
AGTAGCG for 18s.
Graphs and Statistics
All of the graphs (mean  S.D.) were plotted, and statistics
analyses were performed usingMicrosoft Excel software. Two-
tailed, unpaired Student’s t test was carried out in Excel and
one-way ANOVA using SigmaPlot 12.5.
Author contributions—R. V. S., R. B., I. P., and A. M. carried out
experiments and analyzed data; N. S., S. L., and A. W. synthesized
RSK and MSK inhibitors; and J. S. C. A. and R. V. S. wrote the paper
Acknowledgments—We thank Matthias Gaestel (Hannover Medical
University) for the MK2/3 knockout mice and Andre Hanauer (Uni-
versity of Strasbourg) for the RSK1/2 knockout mice.
References
1. Glocker, E. O., Kotlarz, D., Boztug, K., Gertz, E.M., Schaäfer, A. A., Noyan,
F., Perro, M., Diestelhorst, J., Allroth, A., Murugan, D., Hätscher, N., Pfe-
ifer, D., Sykora, K. W., Sauer, M., Kreipe, H., et al. (2009) Inflammatory
bowel disease and mutations affecting the interleukin-10 receptor.
N. Engl. J. Med. 361, 2033–2045 CrossRef Medline
2. Kühn, R., Löhler, J., Rennick, D., Rajewsky, K., and Müller, W. (1993)
Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75,
263–274 CrossRef Medline
3. Glocker, E. O., Frede, N., Perro, M., Sebire, N., Elawad, M., Shah, N., and
Grimbacher, B. (2010) Infant colitis: it’s in the genes. Lancet 376, 1272
CrossRef Medline
4. MacKenzie, K. F., Pattison, M. J., and Arthur, J. S. (2014) Transcriptional
regulation of IL-10 and its cell-specific role in vivo.Crit. Rev. Immunol. 34,
315–345 CrossRef Medline
5. Saraiva, M., andO’Garra, A. (2010) The regulation of IL-10 production by
immune cells. Nat. Rev. Immunol. 10, 170–181 CrossRef Medline
6. Gabryšová, L., Howes, A., Saraiva, M., and O’Garra, A. (2014) The regu-
lation of IL-10 expression. Curr. Top. Microbiol. Immunol. 380, 157–190
Medline
7. O’Garra, A., Barrat, F. J., Castro, A. G., Vicari, A., and Hawrylowicz, C.
(2008) Strategies for use of IL-10 or its antagonists in human disease.
Immunol. Rev. 223, 114–131 CrossRef Medline
8. Siewe, L., Bollati-Fogolin,M.,Wickenhauser, C., Krieg, T.,Müller,W., and
Roers, A. (2006) Interleukin-10 derived frommacrophages and/or neutro-
phils regulates the inflammatory response to LPS but not the response to
CpG DNA. Eur. J. Immunol. 36, 3248–3255 CrossRef Medline
9. Roers, A., Siewe, L., Strittmatter, E., Deckert, M., Schlüter, D., Stenzel,W.,
Gruber, A.D., Krieg, T., Rajewsky, K., andMüller,W. (2004)T cell-specific
inactivation of the interleukin 10 gene in mice results in enhanced T cell
responses but normal innate responses to lipopolysaccharide or skin irri-
tation. J. Exp. Med. 200, 1289–1297 CrossRef Medline
10. Matsushita, T., Horikawa, M., Iwata, Y., and Tedder, T. F. (2010) Regula-
tory B cells (B10 cells) and regulatory T cells have independent roles in
controlling experimental autoimmune encephalomyelitis initiation and
late-phase immunopathogenesis. J. Immunol. 185, 2240–2252 CrossRef
Medline
11. Spach, K. M., Nashold, F. E., Dittel, B. N., and Hayes, C. E. (2006) IL-10
signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibi-
tion of experimental autoimmune encephalomyelitis. J. Immunol. 177,
6030–6037 CrossRef Medline
12. Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D., and Anderton,
S. M. (2002) B cells regulate autoimmunity by provision of IL-10. Nat.
Immunol. 3, 944–950 CrossRef Medline
13. Mauri, C., Gray, D., Mushtaq, N., and Londei, M. (2003) Prevention of
arthritis by interleukin 10-producing B cells. J. Exp. Med. 197, 489–501
CrossRef Medline
14. Watanabe, R., Ishiura, N., Nakashima, H., Kuwano, Y., Okochi, H., Ta-
maki, K., Sato, S., Tedder, T. F., and Fujimoto, M. (2010) Regulatory B
cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10
cell deficiency exacerbates systemic autoimmunity. J. Immunol. 184,
4801–4809 CrossRef Medline
15. Schmidt, E. G., Larsen, H. L., Kristensen, N. N., Poulsen, S. S., Claesson,
M. H., and Pedersen, A. E. (2012) B cells exposed to enterobacterial com-
ponents suppress development of experimental colitis. Inflamm. Bowel.
Dis. 18, 284–293 CrossRef Medline
16. Mauri, C., and Menon, M. (2017) Human regulatory B cells in health and
disease: therapeutic potential. J. Clin. Invest. 127, 772–779 CrossRef
Medline
17. Lampropoulou, V., Hoehlig, K., Roch, T., Neves, P., Calderón Gomez, E.,
Sweenie, C. H., Hao, Y., Freitas, A. A., Steinhoff, U., Anderton, S. M., and
Fillatreau, S. (2008) TLR-activated B cells suppress T cell-mediated auto-
immunity. J. Immunol. 180, 4763–4773 CrossRef Medline
18. Boonstra, A., Rajsbaum, R., Holman, M., Marques, R., Asselin-Paturel, C.,
Pereira, J. P., Bates, E. E., Akira, S., Vieira, P., Liu, Y. J., Trinchieri, G., and
O’Garra, A. (2006)Macrophages andmyeloid dendritic cells, but not plas-
macytoid dendritic cells, produce IL-10 in response toMyD88- and TRIF-
RSK1 and 2 regulate IL-10 induction in B cells
J. Biol. Chem. (2018) 293(7) 2302–2317 2315
 at U
N
IV
ERSITY
 O
F D
U
N
D
EE on February 26, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
dependent TLR signals, and TLR-independent signals. J. Immunol. 177,
7551–7558 CrossRef Medline
19. Barr, T. A., Brown, S., Ryan, G., Zhao, J., and Gray, D. (2007) TLR-medi-
ated stimulation of APC: distinct cytokine responses of B cells and den-
dritic cells. Eur. J. Immonol. 37, 3040–3053 CrossRefMedline
20. Arthur, J. S., and Ley, S. C. (2013) Mitogen-activated protein kinases in
innate immunity. Nat. Rev. Immunol. 13, 679–692 CrossRef Medline
21. Cohen, P. (2014) The TLR and IL-1 signalling network at a glance. J. Cell
Sci. 127, 2383–2390 CrossRef Medline
22. Kim, C., Sano, Y., Todorova, K., Carlson, B. A., Arpa, L., Celada, A., Law-
rence, T., Otsu, K., Brissette, J. L., Arthur, J. S., and Park, J. M. (2008) The
kinase p38 serves cell type-specific inflammatory functions in skin injury
and coordinates pro- and anti-inflammatory gene expression.Nat. Immu-
nol. 9, 1019–1027 CrossRef Medline
23. Cargnello, M., and Roux, P. P. (2011) Activation and function of the
MAPKs and their substrates, theMAPK-activated protein kinases.Micro-
biol. Mol. Biol. Rev. 75, 50–83 CrossRef Medline
24. Arthur, J. S. (2008) MSK activation and physiological roles. Front. Biosci.
13, 5866–5879 Medline
25. Ehlting, C., Ronkina, N., Böhmer, O., Albrecht, U., Bode, K. A., Lang, K. S.,
Kotlyarov, A., Radzioch, D., Gaestel, M., Häussinger, D., and Bode, J. G.
(2011) Distinct functions of the mitogen-activated protein kinase-acti-
vated protein (MAPKAP) kinases MK2 and MK3: MK2 mediates lipopo-
lysaccharide-induced signal transducers and activators of transcription 3
(STAT3) activation by preventing negative regulatory effects of MK3.
J. Biol. Chem. 286, 24113–24124 CrossRef Medline
26. Gaestel, M. (2013) What goes up must come down: molecular basis of
MAPKAP kinase 2/3-dependent regulation of the inflammatory response
and its inhibition. Biol. Chem. 394, 1301–1315 Medline
27. Ananieva, O., Darragh, J., Johansen, C., Carr, J. M.,McIlrath, J., Park, J. M.,
Wingate, A., Monk, C. E., Toth, R., Santos, S. G., Iversen, L., and Arthur,
J. S. (2008) The kinases MSK1 and MSK2 act as negative regulators
of Toll-like receptor signaling. Nat. Immunol. 9, 1028–1036 CrossRef
Medline
28. Elcombe, S. E., Naqvi, S., Van Den Bosch, M. W., MacKenzie, K. F., Cian-
fanelli, F., Brown, G. D., and Arthur, J. S. (2013) Dectin-1 regulates IL-10
production via a MSK1/2 and CREB dependent pathway and promotes
the induction of regulatory macrophage markers. PLoS One 8, e60086
CrossRef Medline
29. Reyskens, K. M., and Arthur, J. S. (2016) Emerging roles of the mitogen
and stress activated kinases MSK1 and MSK2. Front. Cell Dev. Biol. 4, 56
Medline
30. Naqvi, S., Martin, K. J., and Arthur, J. S. (2014) CREB phosphorylation at
Ser133 regulates transcription via distinct mechanisms downstream of
cAMP andMAPK signalling. Biochem. J. 458, 469–479 CrossRefMedline
31. Gee, K., Angel, J. B., Ma, W., Mishra, S., Gajanayaka, N., Parato, K., and
Kumar, A. (2006) Intracellular HIV-Tat expression induces IL-10 synthe-
sis by the CREB-1 transcription factor through Ser133 phosphorylation
and its regulation by the ERK1/2MAPK in humanmonocytic cells. J. Biol.
Chem. 281, 31647–31658 CrossRef Medline
32. Koscsó, B., Csóka, B., Selmeczy, Z., Himer, L., Pacher, P., Virág, L., and
Haskó, G. (2012) Adenosine augments IL-10 production by microglial
cells through an A2B adenosine receptor-mediated process. J. Immunol.
188, 445–453 CrossRef Medline
33. MacKenzie, K. F., Clark, K., Naqvi, S., McGuire, V. A., Nöehren, G., Kris-
tariyanto, Y., van den Bosch, M., Mudaliar, M., McCarthy, P. C., Pattison,
M. J., Pedrioli, P. G., Barton, G. J., Toth, R., Prescott, A., and Arthur, J. S.
(2013) PGE2 induces macrophage IL-10 production and a regulatory-like
phenotype via a protein kinase A-SIK-CRTC3 pathway. J. Immunol. 190,
565–577 CrossRef Medline
34. Clark, K., MacKenzie, K. F., Petkevicius, K., Kristariyanto, Y., Zhang, J.,
Choi, H. G., Peggie, M., Plater, L., Pedrioli, P. G., McIver, E., Gray, N. S.,
Arthur, J. S., and Cohen, P. (2012) Phosphorylation of CRTC3 by the
salt-inducible kinases controls the interconversion of classically acti-
vated and regulatory macrophages. Proc. Natl. Acad. Sci. U.S.A. 109,
16986–16991 CrossRef Medline
35. Baumgarth,N. (2011)The double life of a B-1 cell: self-reactivity selects for
protective effector functions. Nat. Rev. Immunol. 11, 34–46 Medline
36. Rosser, E. C., and Mauri, C. (2015) Regulatory B cells: origin, phenotype,
and function. Immunity 42, 607–612 CrossRef Medline
37. Lykken, J. M., Candando, K. M., and Tedder, T. F. (2015) Regulatory B10
cell development and function. Int. Immunol. 27, 471–477 CrossRef
Medline
38. Mauri, C., and Bosma, A. (2012) Immune regulatory function of B cells.
Annu. Rev. Immunol. 30, 221–241 CrossRef Medline
39. Tedder, T. F. (2015) B10 cells: a functionally defined regulatory B cell
subset. J. Immunol. 194, 1395–1401 CrossRef Medline
40. O’Garra, A., andHoward,M. (1992) IL-10 production byCD5B cells.Ann.
N.Y. Acad. Sci. 651, 182–199 CrossRef Medline
41. McCoy, C. E., Campbell, D. G., Deak, M., Bloomberg, G. B., and Arthur,
J. S. (2005) MSK1 activity is controlled by multiple phosphorylation sites.
Biochem. J. 387, 507–517 CrossRef Medline
42. Aziz, M., Holodick, N. E., Rothstein, T. L., and Wang, P. (2017) B-1a cells
protect mice from sepsis: critical role of CREB. J. Immunol. 199, 750–760
CrossRef Medline
43. Best, J. L., Amezcua, C. A., Mayr, B., Flechner, L., Murawsky, C. M., Em-
erson, B., Zor, T., Gardner, K. H., andMontminy,M. (2004) Identification
of small-molecule antagonists that inhibit an activator: coactivator inter-
action. Proc. Natl. Acad. Sci. U.S.A. 101, 17622–17627 CrossRef Medline
44. Li, B. X., andXiao, X. (2009) Discovery of a small-molecule inhibitor of the
KIX-KID interaction. Chembiochem 10, 2721–2724 CrossRef Medline
45. Romeo, Y., Zhang, X., and Roux, P. P. (2012) Regulation and function of
the RSK family of protein kinases. Biochem. J. 441, 553–569 CrossRef
Medline
46. Dalby, K. N., Morrice, N., Caudwell, F. B., Avruch, J., and Cohen, P. (1998)
Identification of regulatory phosphorylation sites in mitogen-activated
protein kinase (MAPK)-activated protein kinase-1a/p90rsk that are in-
ducible by MAPK. J. Biol. Chem. 273, 1496–1505 CrossRef Medline
47. Jain, R., Mathur, M., Lan, J., Costales, A., Atallah, G., Ramurthy, S., Sub-
ramanian, S., Setti, L., Feucht, P., Warne, B., Doyle, L., Basham, S., Jeffer-
son, A. B., Lindvall, M., Appleton, B. A., et al. (2015) Discovery of potent
and selective RSK inhibitors as biological probes. J. Med. Chem. 58,
6766–6783 CrossRef Medline
48. Aronchik, I., Appleton, B. A., Basham, S. E., Crawford, K., Del Rosario, M.,
Doyle, L. V., Estacio, W. F., Lan, J., Lindvall, M. K., Luu, C. A., Ornelas, E.,
Venetsanakos, E., Shafer, C. M., and Jefferson, A. B. (2014) Novel potent
and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogene-
ity of RSK function in MAPK-driven cancers. Mol. Cancer Res. 12,
803–812 CrossRef Medline
49. Shaw, M., and Cohen, P. (1999) Role of protein kinase B and the MAP
kinase cascade in mediating the EGF-dependent inhibition of glycogen
synthase kinase 3 in Swiss 3T3 cells. FEBS Lett. 461, 120–124 CrossRef
Medline
50. Naqvi, S., Macdonald, A., McCoy, C. E., Darragh, J., Reith, A. D., and
Arthur, J. S. (2012) Characterization of the cellular action of the MSK
inhibitor SB-747651A. Biochem. J. 441, 347–357 CrossRef Medline
51. Miller, R. M., Paavilainen, V. O., Krishnan, S., Serafimova, I. M., and
Taunton, J. (2013) Electrophilic fragment-based design of reversible cova-
lent kinase inhibitors. J. Am. Chem. Soc. 135, 5298–5301 CrossRef
Medline
52. Matsumoto, M., Fujii, Y., Baba, A., Hikida, M., Kurosaki, T., and Baba, Y.
(2011) The calcium sensors STIM1 and STIM2 control B cell regulatory
function through interleukin-10 production. Immunity 34, 703–714
CrossRef Medline
53. Rangaswamy, U. S., and Speck, S. H. (2014) Murine gammaherpesvirus
M2 protein induction of IRF4 via the NFAT pathway leads to IL-10 ex-
pression in B cells. PLoS Pathog. 10, e1003858 CrossRef Medline
54. Ziegler, S., Gartner, K., Scheuermann, U., Zoeller, T., Hantzschmann, J.,
Over, B., Foermer, S., Heeg, K., and Bekeredjian-Ding, I. (2014) Ca2-
related signaling events influence TLR9-induced IL-10 secretion in hu-
man B cells. Eur. J. Immunol. 44, 1285–1298 CrossRef Medline
55. Grammer, A. C., Swantek, J. L., McFarland, R. D., Miura, Y., Geppert, T.,
and Lipsky, P. E. (1998) TNF receptor-associated factor-3 signaling medi-
ates activation of p38 and Jun N-terminal kinase, cytokine secretion, and
Ig production following ligation of CD40 on human B cells. J. Immunol.
161, 1183–1193 Medline
RSK1 and 2 regulate IL-10 induction in B cells
2316 J. Biol. Chem. (2018) 293(7) 2302–2317
 at U
N
IV
ERSITY
 O
F D
U
N
D
EE on February 26, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
56. Mion, F., Tonon, S., Toffoletto, B., Cesselli, D., Pucillo, C. E., and Vitale, G.
(2014) IL-10 production by B cells is differentially regulated by immune-
mediated and infectious stimuli and requires p38 activation.Mol. Immu-
nol. 62, 266–276 CrossRef Medline
57. Risco, A., del Fresno, C., Mambol, A., Alsina-Beauchamp, D., MacKenzie,
K. F., Yang, H. T., Barber, D. F., Morcelle, C., Arthur, J. S., Ley, S. C.,
Ardavin, C., and Cuenda, A. (2012) p38 and p38 kinases regulate the
Toll-like receptor 4 (TLR4)-induced cytokine production by controlling
ERK1/2 protein kinase pathway activation. Proc. Natl. Acad. Sci. U.S.A.
109, 11200–11205 CrossRef Medline
58. Liu, Y. W., Chen, C. C., Tseng, H. P., and Chang, W. C. (2006) Lipopo-
lysaccharide-induced transcriptional activation of interleukin-10 is
mediated by MAPK- and NF-B-induced CCAAT/enhancer-binding
protein delta in mouse macrophages. Cell Signal. 18, 1492–1500
CrossRef Medline
59. Lucas, M., Zhang, X., Prasanna, V., and Mosser, D. M. (2005) ERK activa-
tion following macrophage FcR ligation leads to chromatin modifica-
tions at the IL-10 locus. J. Immunol. 175, 469–477 CrossRef Medline
60. Branger, J., van den Blink, B., Weijer, S., Madwed, J., Bos, C. L., Gupta, A.,
Yong, C. L., Polmar, S. H., Olszyna, D. P., Hack, C. E., van Deventer, S. J.,
Peppelenbosch, M. P., and van der Poll, T. (2002) Anti-inflammatory ef-
fects of a p38 mitogen-activated protein kinase inhibitor during human
endotoxemia. J. Immunol. 168, 4070–4077 CrossRef Medline
61. Foey, A. D., Parry, S. L.,Williams, L.M., Feldmann,M., Foxwell, B.M., and
Brennan, F. M. (1998) Regulation of monocyte IL-10 synthesis by endog-
enous IL-1 and TNF-: role of the p38 and p42/44 mitogen-activated
protein kinases. J. Immunol. 160, 920–928 Medline
62. Ma, W., Lim, W., Gee, K., Aucoin, S., Nandan, D., Kozlowski, M., Diaz-
Mitoma, F., andKumar, A. (2001) The p38mitogen-activated kinase path-
way regulates the human interleukin-10 promoter via the activation of Sp1
transcription factor in lipopolysaccharide-stimulated human macro-
phages. J. Biol. Chem. 276, 13664–13674 CrossRef Medline
63. Wang, F., Marshall, C. B., and Ikura,M. (2013) Transcriptional/epigenetic
regulator CBP/p300 in tumorigenesis: structural and functional versatility
in target recognition. Cell Mol. Life Sci. 70, 3989–4008 CrossRef Medline
64. Dyson, H. J., and Wright, P. E. (2016) Role of intrinsic protein disorder in
the function and interactions of the transcriptional coactivators CREB-
binding protein (CBP) and p300. J. Biol. Chem. 291, 6714–6722 CrossRef
Medline
65. Sanin, D. E., Prendergast, C. T., and Mountford, A. P. (2015) IL-10 pro-
duction in macrophages is regulated by a TLR-driven CREB-mediated
mechanism that is linked to genes involved in cellmetabolism. J. Immunol.
195, 1218–1232 CrossRef Medline
66. Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., McLauchlan, H.,
Klevernic, I., Arthur, J. S., Alessi, D. R., andCohen, P. (2007)The selectivity
of protein kinase inhibitors: a further update. Biochem. J. 408, 297–315
CrossRef Medline
67. McGuire, V. A., Gray, A., Monk, C. E., Santos, S. G., Lee, K., Aubareda, A.,
Crowe, J., Ronkina,N., Schwermann, J., Batty, I. H., Leslie,N. R., Dean, J. L.,
O’Keefe, S. J., Boothby, M., Gaestel, M., and Arthur, J. S. (2013) Cross talk
between theAkt and p38 pathways inmacrophages downstream of Toll-
like receptor signaling.Mol. Cell Biol. 33, 4152–4165 CrossRef Medline
68. Wiggin, G. R., Soloaga, A., Foster, J. M., Murray-Tait, V., Cohen, P., and
Arthur, J. S. (2002) MSK1 and MSK2 are required for the mitogen- and
stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol.
Cell Biol. 22, 2871–2881 CrossRef Medline
69. Zaru, R., Ronkina, N., Gaestel, M., Arthur, J. S., and Watts, C. (2007) The
MAPK-activated kinase Rsk controls an acute Toll-like receptor signaling
response in dendritic cells and is activated through two distinct pathways.
Nat. Immunol. 8, 1227–1235 CrossRef Medline
70. Kotlyarov, A., Neininger, A., Schubert, C., Eckert, R., Birchmeier, C., Volk,
H. D., and Gaestel, M. (1999) MAPKAP kinase 2 is essential for LPS-
induced TNF- biosynthesis. Nat. Cell Biol. 1, 94–97 CrossRef Medline
71. Wingate, A. D., Martin, K. J., Hunter, C., Carr, J. M., Clacher, C., and
Arthur, J. S. (2009) Generation of a conditional CREB Ser133Ala knockin
mouse. Genesis 47, 688–696 CrossRef Medline
72. Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami,
M., Nakanishi, K., and Akira, S. (1998) Targeted disruption of the MyD88
gene results in loss of IL-1- and IL-18-mediated function. Immunity 9,
143–150 CrossRef Medline
73. de Boer, J., Williams, A., Skavdis, G., Harker, N., Coles, M., Tolaini, M.,
Norton, T., Williams, K., Roderick, K., Potocnik, A. J., and Kioussis, D.
(2003)Transgenicmicewith hematopoietic and lymphoid specific expres-
sion of Cre. Eur. J. Immunol. 33, 314–325 CrossRef Medline
74. McGuire, V. A., Ruiz-Zorrilla Diez, T., Emmerich, C. H., Strickson, S.,
Ritorto, M. S., Sutavani, R. V., Weiss, A., Houslay, K. F., Knebel, A.,
Meakin, P. J., Phair, I. R., Ashford,M. L., Trost, M., and Arthur, J. S. (2016)
Dimethyl fumarate blocks pro-inflammatory cytokine production via in-
hibition of TLR induced M1 and K63 ubiquitin chain formation. Sci. Rep.
6, 31159 CrossRef Medline
75. Darragh, J., Soloaga, A., Beardmore, V. A., Wingate, A. D., Wiggin, G. R.,
Peggie,M., andArthur, J. S. (2005)MSKs are required for the transcription
of the nuclear orphan receptors Nur77, Nurr1 and Nor1 downstream of
MAPK signalling. Biochem. J. 390, 749–759 CrossRef Medline
RSK1 and 2 regulate IL-10 induction in B cells
J. Biol. Chem. (2018) 293(7) 2302–2317 2317
 at U
N
IV
ERSITY
 O
F D
U
N
D
EE on February 26, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Stuart Lang, Andrew Woodland and J. Simon C. Arthur
Ruhcha V. Sutavani, Iain R. Phair, Rebecca Barker, Alison McFarlane, Natalia Shpiro,
macrophages and B cells reveals a role for p90 ribosomal S6 kinases
induced interleukin-10 induction in−Differential control of Toll-like receptor 4
doi: 10.1074/jbc.M117.805424 originally published online December 11, 2017
2018, 293:2302-2317.J. Biol. Chem. 
  
 10.1074/jbc.M117.805424Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/293/7/2302.full.html#ref-list-1
This article cites 75 references, 35 of which can be accessed free at
 at U
N
IV
ERSITY
 O
F D
U
N
D
EE on February 26, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
